Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:07 2024-05-17 EDT			5-day change	1st Jan Change
27.94 ^EUR	-2.03%		-2.55%	-0.46%

05-17	What does the new atlas mean for the 'hospital jungle'?	DP
05-17	Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative	MT

FRESENIUS SE : Gets a Neutral rating from JP Morgan

May 08, 2024 at 07:21 am

Initially Neutral on the company, JP Morgan's analyst David Adlington maintained his recommendation. The target price is still set at EUR 32.50.

Latest news about Fresenius SE & Co. KGaA

What does the new atlas mean for the 'hospital jungle'?	05-17	DP
Moody’s Revises Outlook on Fresenius Medical Care to Stable from Negative	05-17	MT
Launch of new quality atlas for hospitals	05-17	DP
Moody’s Affirms Fresenius' Rating, Outlook on Improving Profitability	05-16	MT
Union demands Lauterbach approach the federal states on hospital reform	05-16	DP
Dobrindt demands approach to federal states on hospital reform	05-16	DP
Lauterbach's 'revolution' for clinics on the way	05-15	DP
Cabinet launches hospital reform	05-15	DP
Cabinet to get hospital reform underway	05-15	DP
FRESENIUS SE : Receives a Buy rating from DZ Bank	05-14	ZD
FRESENIUS SE : Jefferies reiterates its Buy rating	05-14	ZD
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	05-13
FRESENIUS SE : Barclays gives a Buy rating	05-13	ZD
FRESENIUS SE : Berenberg gives a Buy rating	05-13	ZD
Fresenius Medical sees up to 2% US dialysis growth by year-end	05-11	RE
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	05-10	MT
FRESENIUS : Preparing for a strong(er) future performance	05-10
FRESENIUS SE : Deutsche Bank keeps its Buy rating	05-09	ZD
Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup	05-08	DJ
Home REIT cuts borrowings, Genflow shares restored	05-08	AN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	05-08	MT
Fresenius becomes more optimistic thanks to subsidiary Kabi - exit from Vamed	05-08	DP
UBS rates Fresenius SE as 'Buy' - Target 34 euros	05-08	DP
Dpa-AFX Overview: COMPANIES from 08.05.2024 - 15:15	05-08	DP
FRESENIUS SE : Berenberg reiterates its Buy rating	05-08	ZD

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-07-30 - Q2 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : Preparing for a strong(er) future performance

May 10, 2024 at 03:46 am

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.94 EUR

Average target price

36.41 EUR

Spread / Average Target

+30.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-0.46%	17.11B
HCA HEALTHCARE, INC.	+19.28%	84.56B
CVS HEALTH CORPORATION	-26.95%	72.41B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+4.58%	27.75B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.35%	17.75B
QUEST DIAGNOSTICS INCORPORATED	+4.69%	16.03B
REDE D'OR SÃO LUIZ S.A.	+8.14%	13.72B
NATERA, INC.	+69.96%	13.07B
FRESENIUS MEDICAL CARE AG	+6.59%	12.91B
TENET HEALTHCARE CORPORATION	+70.00%	12.55B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Gets a Neutral rating from JP Morgan

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services